Tecarfarin Receives Orphan Drug Designation For Second Indication

FY2023 Reported With Continued Progress Toward The Phase 3 Tecarfarin Trial

Peer-Reviewed Journal Reviews Uses of DOAC Drugs, Pointing To The Need For Tecarfarin

Addressing Unmet Anticoagulation Needs In Orphan Populations

Robert LeBoyer

Virtual & In-person Roadshows / Conferences

Channelchek Premium. Access more at no cost. 

The site "channelcheck" is opened on the phone

Join the Channelchek Investor Community. Your name, email, zip, and investor type is all it takes to open the door to research reports, favorites tracking, and virtual and in-person roadshows / conferences. Even exclusive investment opps.

Take it to the next level. It doesn’t cost a penny.

<p>Click “Log In” to agree to Channelchek.com <a href="#">Terms of Use</a> and acknowledge that Channelchek.com <a href="#">Privacy Policy</a> applies to you.</p>


Welcome to the Channelchek Investor Community

Informed investors make more money. And it’s all about timing. Get it when it happens.

Cadrenal Therapeutics Inc. (CVKD)

Tecarfarin Receives Orphan Drug Designation For Second Indication

Fundamental Analysis:

Rating: Log in to view

Tecarfarin Receives Orphan Drug Designation For Second Indication (CVKD)

FY2023 Reported With Continued Progress Toward The Phase 3 Tecarfarin Trial (CVKD)

Peer-Reviewed Journal Reviews Uses of DOAC Drugs, Pointing To The Need For Tecarfarin (CVKD)

Addressing Unmet Anticoagulation Needs In Orphan Populations (CVKD)

Inbox Intel from Channelchek.